Stealth BioTherapeutics investigates SBT-272 to treat mitochondrial dysfunction in ALS
SBT-272, in the pipeline at Stealth BioTherapeutics, is a new peptidomimetic being investigated as a potential therapy for...
News & Updates
FDA approves oral edavarone to treat adults living with ALS
FDA has approved Radicava ORS (edaravone) oral suspension for the treatment of adults with amyotrophic lateral sclerosis (ALS). Radicava...
Sayuri Miyamoto to present a poster at the Paris Redox 2022 World Conference
NDR is pleased to congratulate Dr. Sayuri Miyamoto and her co-workers Adriano Chaves-Filho, Rosangela Santos, Rodrigo Lima, Larissa...
Cornerstone for ALS Researchers
We are pleased to announce that Dr. Steve Pelech, Kinexus Bioinformatics Corp, completed a long time goal with funding help from NDR....
Research notes from Dr. Miyamoto
We are pleased to let you hear Dr. Sayuri Myiamoto present her preliminary work, listen to the video. There is a lot more to learn, and...
Welcome Dr. Anthony Akkari
We welcome Dr. Anthony Akkari, newest member to our scientific discussion group at NDR. He wears three professional hats. Dr. Akkari is a...
Dr. Susanne Petri Joins NDR Scientific Group
NDR Inc is pleased to announce that Dr. Susanne Petri has joined our scientific group. Dr. Petri is an Associate Professor in the...
NDR funds novel work in ALS research
Dr. Chandler Walker and his team at the Department of Biomedical Sciences and Comprehensive Care at Indiana University School of...
Mesocyte Therapeutics puts ASC secretome therapy into the ALS patient pipeline
Dr. Chandler L. Walker and his laboratory at Indiana University-Purdue University-Indianapolis, study pre- and post-symptomatic pathology...
Bringing a treatment closer to patients
Dr. Gerardo Morfini and his co-workers at the University of Illinois study the basic biology of neurodegenerative diseases. One area of...
NDR awards $1.54 M drug development contract to WuXi App Tec
New drug development
Student Grant Awarded to Rodrigo Santiago Lima
Student grants in ALS